ClinicalTrials.gg
RecruitingNCT06629389CBD-EP-2Updated Dec 5, 2024

Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease Symptoms

A Phase 2 interventional study of Cannabidiol 100 mg/ml and cannabidiol 300 mg/ml in Parkinson Disease, sponsored by Laboratorio Elea Phoenix S.A.. Recruiting at 1 site in Argentina. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-05.

Sponsored by Laboratorio Elea Phoenix S.A. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Parkinson Disease with a site in Argentina — 3 open to participants now, 3 under way, none of them phase 3. Parkinson Disease · Argentina.

Planned enrollment
13th of 15
88 · median 420
Started
2024
the only one that year
Phase 2
3 of 19
1 open now
Registered
19th of 19
by date
Lead sponsor
1 of 19
Laboratorio Elea Phoenix S.A.

Among the 19 studies in Parkinson Disease with a site in Argentina, this one is the 13th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 2, and was the 19th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

3 of the 19 studies in Parkinson Disease with a site in Argentina are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Parkinson Disease with a site in Argentina, or all of them as a file.
02

Study summary

Parkinson disease (PD) is a chronic, progressive neurodegenerative disorder characterized by clinical motor and non-motor symptoms. Knowing the potential benefits has led to the use of cannabis as an alternative therapy.

Read the detailed description

To evaluate safety and tolerability of CBD-based drug product at different doses

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • parkinson disease
  • Cannabidiol
  • oil
  • cannabis
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants between 40 and 80 years old.
  2. Participants diagnosed with PD according to Movement Disorder Society Clinical Diagnostic Criteria for Parkinson\'s disease (72), and to the Brain Bank Criteria for Parkinson\'s disease, with mild to moderate disease as measured by the modified Hoehn and Yahr scale. (Both clinical criteria are included since many of the study participants were diagnosed with previous criteria and others with current criteria, both of which are very similar and do not change or raise any doubt about the diagnosis of the disease).
  3. Participants who have not changed their anti-Parkinson's drugs (or dose) at least one month prior to study entry.
  4. Acceptance by the participant by signing the ICF.
  5. Subjects capable of giving consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  1. Evidence of dementia, score less than 24 or with previous diagnosis by cognitive assessment .
  2. Severe psychiatric pathology: severe depression, treatment- psychosis. Evaluation by psychiatrist who confirms the pathology. History of hospitalization in a psychiatric center or mental health center is an exclusion criterion regardless of the time spent since hospitalization or the reason for which the patient was hospitalized.
  3. Known or suspected allergy to cannabinoids or inactive ingredients used in the formulation of the study drug.
  4. History of drug or alcohol dependence.
  5. Use of dopamine blockers within 180 days prior to study entry.
  6. Use of amphetamine inhibitors, cocaine and MAO-A inhibitors within 90 days prior to study entry.
  7. Patients who have received within 90 days prior to study entry the following drugs due to drug interactions: valproic acid, felbamate, niacin (nicotinic acid) at doses ≥2000mg/day or nicotinamide (nicotinic acid amide or nicotinamide) at doses ≥3000mg/day, isoniazid, ketoconazole and/or clobazam.
  8. Unstable medical condition detected by the following laboratory alterations: \<10g/dL, Leukocytes\<4000 u/ml, Neutrophils\<1500 u/ml, Lymphocytes\<500u/ml, \<100000 u/ml, (AST) and alanine aminotransferase (ALT)> 3 times the .
  9. Moderate-severe liver disease. ( B-C)
  10. Pregnant or breastfeeding.
  11. Women of reproductive age who do not agree to use at least one method of proven efficacy (diaphragm or partner using condom, oral or implanted hormonal contraceptive; intrauterine device, stable partner with vasectomy), until at least four weeks after completion of study treatment. Pregnancy blood test will be performed before starting the study.
  12. Participants who have had a surgical procedure for PD, either deep brain stimulation or surgery for lesion.
  13. Patients de novo or with recent diagnosis of PD (less than 5 years).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
88 participants (estimated)

Study arms

  • Active comparator
    Group CBD 100

    The following dose regime for the 4 treatment arms will be used

    Drug: Cannabidiol 100 mg/ml

  • Active comparator
    Group CBD 300

    The following dose regime for the 4 treatment arms will be used

    Drug: cannabidiol 300 mg/ml

  • Active comparator
    Group CBD 400

    The following dose regime for the 4 treatment arms will be used

    Drug: Cannabidiol 100 mg/ml · Drug: Cannabidiol 400 mg/ml

  • Placebo comparator
    Group Placebo

    The following dose regime for the 4 treatment arms will be used

    Drug: Placebo

Interventions

  • DrugCannabidiol 100 mg/ml

    Drug page: Cannabidiol

    The following dose regime for the 4 treatment arms will be used: DOSE TITRATION PERIOD: First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator.

    Also known as: CBD, Cannabis

  • Drugcannabidiol 300 mg/ml

    Drug page: Cannabidiol

    The following dose regime for the 4 treatment arms will be used: DOSE TITRATION PERIOD: First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator.

  • DrugCannabidiol 400 mg/ml

    Drug page: Cannabidiol

    The following dose regime for the 4 treatment arms will be used: DOSE TITRATION PERIOD: First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator.

  • DrugPlacebo

    The following dose regime for the 4 treatment arms will be used: DOSE TITRATION PERIOD: First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator.

06

What researchers measure

Primary outcomes

  1. Number of patients with advers events related to treatment acording to CTCAE v5.0

    Frequency of adverse events by a global comparison of all dose or placebo groups Range: 1 to 5 Higher values represent a worse disease state

    Time frame: up to 21 weeks

Secondary outcomes

  1. Changes in differents motors scales in Parkinson desease

    changes in the Unified Parkinson's Disease Rating Scale scale (MDS-UPDRS) part I (mental section), part II (daily activities), part III, (motor section), and part IV (treatment complications). Overall range (Part I+II+III+IV): 0 to 260 Higher values represent a worse disease state

    Time frame: up to 15 weeks

  2. Changes in the off periods in Parkinson desease

    • variations in the off periods using the patient's personal diary

    Time frame: up to 15 weeks

  3. Changes in the patients Clinical Global Impression in Parkinson desease

    • changes in the patients Clinical Global Impression as measured by the Clinical Global Impression-Severity Scale (CGI-S). Range: 0 to 7 Higher values represent a worse disease state

    Time frame: up to 21 weeks

  4. Changes in the quality-of-life in Parkinson desease

    • changes in the quality-of-life scale with the Parkinson's Disease Questionnaire (PDQ39). Range: 0 to 100 Higher values represent a worse disease state

    Time frame: up to 15 weeks

  5. Changes in differents no motors symproms in Parkinson desease

    • changes in non-motor symptoms by means of Non-Motor Symptom Scale (NMSS) and Non-Motor Symptoms Questionnaire (NMSQ).

    Time frame: up to 15 weeks

  6. Changes in depression in Parkinson desease

    • changes in depression with the Beck Depression Inventory Scale (BDI-II). Overall range: 0 to 63. Higher values represent a worse disease state

    Time frame: up to 15 weeks

  7. Changes in sleep in Parkinson disease

    • changes in the sleep scale for Parkinson Desease with Epworth Scale. Overall range: 0 to 24. Higher values represent a worse disease state

    Time frame: up to 15 weeks

  8. Changes in Cognitive Assessment in Parkinson desease

    To assess the Montreal Cognitive Assessment (MoCA) scale Maximum score 30 Score greater than 26 is considered normal

    Time frame: up to 15 weeks

  9. Changes in apathy in Parkinson desease

    • changes in apathy measured by the Apathy Evaluation Scale (AES). Total score ranges: 18 to 72 Higher scores indicating more apathy

    Time frame: up to 15 weeks

  10. Changes in pain in Parkinson desease

    • DP pain-related changes measured by the King's Parkinson's Disease Pain Scale (KPSS). Range: 0 to 168 Higher values represent a worse disease state

    Time frame: up to 15 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2025, 12 months after the start.

Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's planned 12 months is below that.

Counting every sponsor, half of 202 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2024
First posted
Oct 8, 2024
StartActual
Nov 28, 2024
Primary completionEst.
Nov 2025
CompletionEst.
Nov 2026
Last update
Dec 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06629389
Lead sponsor
Laboratorio Elea Phoenix S.A.
Responsible party
Sponsor
First posted
Oct 8, 2024
Start date
Nov 28, 2024
Primary completion
Nov 2025 (estimated)
Completion
Nov 2026 (estimated)
Last update
Dec 5, 2024

Study contacts

Maria Daniela Di Leo, MD
Contact
daniela.dileo@elea.com
1144898300
Marcelo A Tinelli, MD
Contact
marcelo.tinelli@elea.com
1144898300
Marina Sanchez Abraham, Neurologa
principal investigator · Hospital Español de Mendoza

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion